COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS. (12th June 2019) - Tarantelli, C.